The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, ...

Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides ...

Solventum has appointed former Zimmer Biomet executive Rachel Ellingson as chief strategy and corporate development officer.

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...

Well, welcome to the 45th Annual TD Cowen Healthcare Conference. I'm Dan Brennan, follow Tools and Diagnostics. Really pleased to be joined on stage here with Marc Casper, Chairman and President of ...

GlobalData analyst Dr Andrew S Thompson expects the deal to prompt a "shuffle" in Thermo Fisher’s life sciences unit.

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Notably, in conjunction with the acquisition, Thermo Fisher issued public comments which Trian believes confirm that there is a meaningful cost reduction opportunity at Solventum: "Excluding financing ...